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Abstract
Background: Cystinuria is an inherited metabolic disease that is caused by defects in two genes, SLC3A1 and
SLC7A9, which result in a renal reabsorptive defect of cystine and other dibasic amino acids, including ornithine,
arginine, and lysine. Patients usually present with recurrent renal calculi and may develop renal impairment. Medical
management includes high fluid intake and chelating agents. To the best of our knowledge, this is the first study
describing cystinuria in Saudi Arabia.
Methods: A retrospective chart review for cystinuria patients from the genetic and nephrology divisions between
2010 to 2015. All patients were investigated, diagnosed and treated at King Abdulaziz Medical City in Saudi Arabia.
Results: Eight patients were identified from five unrelated families. The age of onset ranged from birth to 14 years.
The female to male ratio was 1.7:1. Two new variants in the SLC3A1 and SLC9A7 genes were discovered. All of the
detected mutations were missense variants in three different exons, such as c.1711 T > A (p.Cys571Ser) (exon 10), c.
1166C > T p.Thr389Met (exon 11) and c.1400 T > A p.Met467Lys (exon 8). Additionally, 37.5% of our patients
developed arterial hypertension and 25% had urinary tract infection, but none had renal impairment. No significant
clinical differences were detected in this study between type A (SLC3A1 variants) and type B cystinuria (SLC7A9
variant). Two cases were diagnosed based on clinical information, biochemical testing and a positive family history
as all of the molecular testing for cystinuria was negative.
Conclusion: Cystinuria has wide genetic heterogeneity with a poor genotype/phenotype correlation. Negative
molecular investigations should not rule out the disease if clinical and biochemical investigations support the
diagnosis. A larger data registry is essential to better describe the cystinuria genotype/phenotype in Saudi Arabia.
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Background
Cystinuria continues to be one of the most challenging
stone diseases [1], which has a recurrence rate up to
60%. It is associated with progressive renal impairment
[2]. Cystinuria is one of four genetic metabolic diseases
discovered by Carrod in 1908 [3]. A recent study
published from our center predicted the incidence of
cystinuria to be 4.5/100,000 live births [4].
Thus far, cystinuria is thought to be caused by defects
in two genes, SLC3A1 and SLC7A9. SLC3A1 (MIM
#104614) is located on chromosome 2 (2P16.3) and en-
codes the heavy subunit of the renal amino acid trans-
porter (rBAT) needed to localize the transporter to the
plasma membrane. The SLC7A9 gene (CSNU3, MIM
#604144) is located on chromosome 19 (19q13.1) and
encodes the light subunit of the renal amino acid
transporter (b0,+AT), which compromises the catalytic,
transporting component. The Rbat/B0,+AT is linked by
a disulfide bridge [5–7]. The mode of transmission
seems to be autosomal recessive or autosomal dominant
with incomplete penetrance [8, 9].
Amino acid transport defects cause hyper-excretion
and insolubility of cystine and other dibasic amino acids
as well as precipitation of cystine at the physiological pH
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of urine, which results in recurrent cystine renal calculi,
obstructive uropathy, hypertension, infection and rarely
renal failure [10]. More than 50% of cystinuric patients
develop cystine urolithiasis, and 75% of them have bilat-
eral stones. Recurrent stone formation requires repeated
urological interventions [11, 12].
The diagnosis of cystinuria is achieved by functional,
biochemical or molecular investigations. Functionally,
patients excreting cystine more than 120 mmol/mol cre-
atinine in 24 h urine are defined as having cystinuria [3].
Biochemically, cystinuria is divided into two subtypes
based on the amount of cystine excreted in the urine.
For type 1 cystinuria, which has an autosomal recessive
mode of transmission, heterozygotes have normal amino
acid excretion. On the other hand, for non-type 1 cystin-
uria, heterozygotes have cystine hyper-excretion, indicat-
ing an autosomal dominant mode of transmission with
incomplete penetrance [9]. Molecularly, mutations in
the SLC3A1 gene cause type A cystinuria, while type B is
due to SLC7A9 gene mutations. A possible third type,
AB, has mutations in both genes [8]. Although it was
proposed that SLC3A1 mutations (type A) cause type
1 cystinuria and SLC7A9 mutations (type B) cause non-
type 1 cystinuria, an increasing number of SLC3A1 vari-
ants were discovered to cause cystine and other dibasic
hyper-aminoaciduria in carriers in addition to several
point mutations in SLC7A9, resulting in silent heterozy-
gotes [10].
The treatment success in cystinuria patients depends
on full compliance with medical therapy, including urine
alkalization with potassium citrate and dietary sodium
restriction. High fluid intake has been shown to decrease
urinary stone formation in up to 67% of patients with
cystinuria, achieving a urine specific gravity of 1.010.
The most effective chelating agent for cystinuria is oral
thiol (β,β-dimethylcystine), which forms mixed disulfides
with cystine, dissolving and reducing new cystine stone
formation [13].
In this study, we described the clinical phenotype and
genotype of eight Saudi patients with cystinuria. To the
best of our knowledge, this is the first study in the litera-
ture describing the clinical, biochemical and molecular
characteristics of cystinuria in Saudi Arabia.
Methods
A retrospective chart review of eight Saudi cystinuric
patients from five unrelated families between 2010 to
2015. All patients were diagnosed and treated at King
Abdulaziz Medical City in Saudi Arabia under the care
of a multidisciplinary team, including nephrologists and
geneticists.
The diagnosis was clinically established based on recur-
rent cystine renal calculi formation that started in child-
hood. Other biochemical, radiological and molecular
investigations were requested to confirm the diagnosis.
Investigations that were performed include abdominal
X-Ray, ultrasound, abdominal CT, stone analysis, urinary
amino acid study and molecular genetic testing. Amino
acids in urine were measured using early morning fresh
urine samples and 24-h urine. DNA sequencing analysis,
coding sequences of the SLC3A1 and SLC7A9 genes and
mutational analysis were performed at referenced com-
mercial labs. The SLC3A1(NM_000341) and SLC7A9
(NM_014270) genes were analyzed by PCR and sequen-
cing of both DNA strands of the coding introns and
highly conserved exon-intron splice junctions.
Results
Clinical data (Table 1)
All patients were products of consanguineous parents.
They presented with renal stone related signs and symp-
toms; five patients presented with bilateral renal calculi
and three had unilateral stones. The ages of onset were
variable, ranging from birth to 14 years (mean 6.3 years).
The current age of the oldest patient is 24 years. The
female to male ratio was 1.7:1. A positive family history
was documented in seven cases. Three cases developed
hypertension and two cases had recurrent urinary tract
infections (UTI).
All parents were asymptomatic. Renal ultrasound and
urine amino acids were done for the parents and the
results were negative.
Biochemical and molecular features (Table 2)
All cases had high urinary dibasic amino acids levels at
diagnosis with variable severity. Stone analysis showed
yellow–white formation with waxy lusters and cystine.
The renal profile remained within normal limits for all
patients.
Molecular study showed previously unreported mis-
sense variant in exon 10 of SLC3A1 gene (c.1711 T > A
p.Cys571Ser) in two cases (Patients 2 and 3). This vari-
ant is located in a highly conserved nucleotide and
amino acid position with moderate physiochemical dif-
ferences between the amino acid cysteine and serine.
Software analyses by Polyphen-2 and Mutation Taster
predicted that the mutation is probably damaging. An-
other new variant in exon 11 of the SLC9A7 gene
(c.1166 C > T p.Thr389Met) was found in one patient
(Patient 5). This variant was also located in a highly
conserved nucleotide and moderately conserved amino
acid position, and there were moderate physiochemical
differences between the amino acids threonine and
methionine. Software analyses by Polyphen-2 and SIFT
predict this variant is probably damaging. A previously
reported mutation in exon 8 of the SLC3A1 gene
(c.1400 T >A p.Met467Lys), described as disease-causing
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by Calonge in 1994 (PMID 8054986), was observed in
three patients.
Imaging features (Table 3)
All discovered stones were radio-opaque. According
to abdominal X-ray, renal ultrasound, and abdominal
CT scan studies, we found six cases with multiple bi-
lateral cystine calculi of variable sizes; two of them
were staghorn and two cases had unilateral, multiple
stones. DMSA scanning showed a unilateral decrease
in renal function that had mild severity in two cases
and an atrophic small right kidney in another two cases.
Course of the disease
Currently, all patients are in stable condition with
variable responses to treatment; five patients were on
regular treatment with Tiopronin and potassium citrate
and three patients were on penicillamine and potassium
citrate. Only one male patient underwent right nephrec-
tomy. Six patients were surgically treated by percutan-
eous nephrolithotomy.
Discussion
Cystinuria is a rare genetic disease caused by a proximal
renal reabsorptive defect of filtered cystine leading to
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Case 3 23 y Female brother 12 years No No Right side Potassium citrate
Tiopronin
ESWL
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Cousin










Case 7 11 y Female Grandmother
Brother, sister





Case 8 16 y Male Grandma Brother
and sister




UTI Urinary tract infection and HTN Hypertension
Table 2 Biochemical and molecular features
Biochemical Molecular
Amino acidsa SLC3A1 Exon SLC9A7
Cases Cys. Arg. Orn. Lys.
Case 1 160 790 177 1179
Case 2 98 337 163 267 c.1711 T > A p.571Cys571Ser 10
Case 3 310 3885 508 772 c.1711 T > A p.571Cys571Ser 10
Case 4 211 558 350 718
Case 5 211 224 97 357 11 c.1166 C > T p.Thr389Met
Case 6 177 557 235 594 c.1400 T > A p.Met467Lys 8
Case 7 112 244 108 197 c.1400 T > A p.Met467Lys 8
Case 8 93 177 83 158 c.1400 T > A p.Met467Lys 8
aCut off: cystine: 4–12 μmol/mmol crea.; ornithine: 0–6 μmol/mmol crea.; arginine 0–6 μmol/mmol crea.; and lysine: 10–56 μmol/mmol crea
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recurrent stone formation [14]. In our study, the age of
onset was variable, ranging from birth to 14 years (mean
6.3 years), which is partially consistent with the expected
age of the onset of stone formation in cystinuria in the
first decade of life and continues lifelong, peaking during
the third decade [8, 15]. In a study on Sudanese patients,
the mean age at presentation with cystine stones was
31.9 months (range 3–125 months) [16].
In cystinuria, the male to female ratio used to be
nearly equal [9]. On the other hand, in our study, fe-
males were affected nearly twice as much as males
(ratio1.7: 1). Other studies in the Middle East reported
a reverse finding with a male to female ratio of 2.3:1
[16]. Two of our patients developed staghorn calculi,
supporting the expected natural course of the disease,
and they had recurrent and multiple bilateral renal
stones [15]. The structure and composition of the
stones of our patients mimic the typical composition
of cystine stones [16].
Furthermore, 34% of patients with cystine calculi
might present with signs of UTI and hypertension; there
can be renal failure in up to 17% [6, 7]. In our study,
two patients (25%) presented with renal calculi and UTI.
Hypertension developed in three cases (37.5%), but there
was no renal impairment, which might be due to early
detection and proper management.
Although the most frequent mutation in the
Mediterranean region in the SLC3A1 gene is M467T
[17], three of our patients (37.5%) from a single family
were homozygous for the less common M467L muta-
tion, which was previously reported by Calonge, M. et al.
(1995) as compound heterozygous. Different regions of
the world show characteristic mutation frequencies; for
example, p.T216M in SLC3A1 and p.G105R in SLC7A9
are common in Greece [18]. In Portuguese, deletion and
duplication (accounts 33.3%), especially E5_E9 Dup, are
the most common, while c.1400 T > C p.M467T
accounted for 11.1% of mutated alleles. This reflects the
importance of screening for large deletion/duplication
mutations in cystinuria patients. Furthermore, even if
patients were negative, the negative finding does not rule
out the disease [10]. Two of our patients (25%) did not
show any pathogenic mutations in the target genes; more-
over, their deletion/duplication study was also negative. As
Table 3 Imaging features
Case DMSA Renal CT Renal US
Case 1 Right kidney: Relatively Reduced volume,
Split renal function 61%
Left kidney. Cortical scarring at the upper
pole & large photopenic area in the lower
pole with Split renal function 39%
Right kidney: large staghorn
branching stone on the renal pelvis
Left kidney: left renal lower pole stone
Right kidney: grade 3
hydronephrosis




Case 2 Right kidney small with decrease uptake
and small scar
Left good kidney uptake with split renal
function 92%
Right kidney: Atrophic small right
kidney with at least two calculi
at its lower pole
Left kidney: A tiny calculus at the
left vesicoureteric junction.
Right kidney: Small size,
lower pole mild to moderate
hydronephrosis.
Left kidney: non-obstructing
calculus noted at the lower
pole with mild hydronephrosis.
Case 3 Right kidney: obstructive right
periureteric junction stone with
moderate hydronephrosis.
Left kidney: normal
Right kidney: calculi in the pelvis
with moderate hydronephrosis.
Case 4 Right kidney: large stone in the
renal pelvis. Small calculus in the
lower pole of an atrophic, small kidney.
Left kidney: large calculus in the
left renal pelvis. Severe hydronephrosis
and thinning of the cortex. Multiple
non-obstructing calculi seen in the
lower pole.
Right kidney: grade 2
hydronephrosis, multiple
non-obstructing stones.
Left kidney: grade 4
hydronephrosis with thin
renal parenchyma and an
obstructive stone
Case 5 Bilateral renal stones
Case 6 Normal right kidney according to DMSA
scintigraphy, with reduced left kidney
function, hydronephrotic changes, and a scar.
Right kidney: normal
Left kidney: multiple
stones and grade 1
hydronephrosis.
Case 7 Left non-obstructive renal stones.
Case 8 Right Kidney: Calculi in
the pelvis
Left Kidney: Normal
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a result, the patients were diagnosed based on clinical and
biochemical results.
In our study, all detected variants were caused by
point mutations of the missense type. This is in contrast
with previously reported mutations that are nonsense,
splicing, small rearrangement and gross rearrangement
mutations (insertion and deletion) [10]. Thus far, more
than 160 mutations have been discovered in the SLC3A1
gene and more than 116 mutations have been discovered
in the SLC7A9 gene. [1].
We identified two novel mutations in the SLC3A1 and
SLC7A9 genes. Both variants where located in highly
conserved positions, and they are predicted to be
damaging according to software analyses. Additionally,
they segregated well in the families, which supports the
causality for the patient’s phenotype. These newly
described variants support and expand on the allelic het-
erogeneity and complexity of genes variants previously
described in cystinuria [19]. The phenotypes of the
newly discovered mutations mimic the classical cystin-
uria phenotype.
Although the missense variant, G105R, has been re-
ported as one of the most frequent mutations in the
SLC7A9 gene in cystinuria patients, mainly in Europe
[9], it was not found in any of our patients.
In our study, the long-term complications of cystinuria
were less than those mentioned in the literature. This
may be explained by the early detection and aggressive
management of disease. Accordingly, we recommend
early screening and diagnosis for other children from af-
fected families.
Conclusion
The newly described mutations result in a classical cystin-
uria picture. The most frequent mutation discovered in
our study was in the SLC3A1 gene, M467L. Negative mo-
lecular testing does not rule out the disease if patients are
symptomatic. Cystinuria should be considered in each
child who has a renal stone and UTI with or without posi-
tive family history. Some patients might develop hyperten-
sion and UTI, but they do not necessarily have end-stage
renal disease especially if diagnosed early and managed
properly. No significant clinical differences were detected
in this study between types A and B cystinuria. Screening
for children in affected families is recommended. A larger
data registry is essential for better describing the cystinuria
genotype/phenotype in Saudi Arabia.
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